📌 Key Takeaways
- On July 17, 2026, the EU approved Boey® (trenibotulinumtoxinE) —
the world’s first Serotype E botulinum toxin for cosmetic use,
covering all 30 EEA member states. - Unlike conventional Botox (Serotype A, lasting 3–6 months),
Boey® effects onset as early as 8 hours and resolve in approximately 2–3 weeks. - The U.S. FDA issued a Complete Response Letter (CRL) in April 2026 —
requesting additional manufacturing data only,
not raising safety or efficacy concerns. - Canada was the first country to approve Boey® in June 2026;
the EU followed in July.
No approval timeline has been announced for other markets.
“What if I hate the result and I’m stuck with it for six months?”
For many people curious about aesthetic injectables,
that fear is the single biggest barrier to trying Botox.
The irreversibility of conventional neuromodulators has long been the defining limitation of the category.
On July 17, 2026, Allergan Aesthetics (AbbVie) announced EU approval of Boey® (trenibotulinumtoxinE) —
a neurotoxin that works differently at a molecular level,
and wears off in roughly two to three weeks.
For the first time, patients can choose not just whether to try a neuromodulator,
but how long they want the effect to last.
INDEX
What Is Boey®? The Significance of Serotype E
Botulinum toxin exists in seven serotypes (A through G).
Every commercially available aesthetic neuromodulator —
Botox, Dysport, Xeomin, Daxxify — is based on Serotype A.
Boey® is the first product approved for cosmetic use based on Serotype E,
which acts through a distinct molecular mechanism,
resulting in a different onset speed, duration, and side-effect profile.
All existing botulinum toxin products on the market share the same serotype classification: Serotype A.
Boey® breaks from this entirely, using Serotype E (trenibotulinumtoxinE) —
a first in the history of approved aesthetic neuromodulators.
Canada’s Health Canada was the first regulatory body to approve Boey® in June 2026.
The European Commission followed on July 17, 2026,
making the EU the second jurisdiction to grant approval.
Why Does Boey® Wear Off So Quickly? The Mechanism
Both Serotype A and Serotype E target SNAP-25,
the synaptic protein responsible for controlling neurotransmitter release.
The key difference lies in the half-life of the light chain.
Serotype E’s light chain has a significantly shorter half-life than Serotype A’s.
This shorter half-life is what drives both the rapid onset (as early as 8 hours)
and the brief duration (approximately 2–3 weeks).
Serotype E also enables faster cellular uptake and translocation into nerve cells,
contributing to its accelerated action profile.
Source: Clival / AbbVie official documentation
EU Approval, Canada Approval, and the U.S. FDA Status
In the United States, AbbVie announced on April 23, 2026 that it had received a Complete Response Letter (CRL) from the FDA.
A CRL is not a rejection — it is a formal request for additional information before a final decision can be made.
The FDA’s request was limited to manufacturing process data;
no concerns were raised regarding the safety or efficacy of the product itself.
AbbVie has indicated its intention to respond to the FDA’s request within months.
In parallel, the company is advancing commercial launch preparations in Europe
and developing healthcare professional education programs.
A specific commercial launch date in the EU had not been officially announced as of July 2026.
Phase 3 Clinical Trial Data Supporting EU Approval
Design: Randomized, double-blind, placebo-controlled, multicenter
Participants: 725 adults with moderate-to-severe glabellar (frown) lines
Dose: Boey® 700 units or placebo
Primary endpoint: Facial Wrinkle Scale (4-point scale),
assessed by clinician + patient + natural appearance evaluation
Composite responder rate at Day 7:
— M21-500: 60.0% (vs. placebo; p<0.0001)
— M21-508: 65.7% (vs. placebo; p<0.0001)
Reported adverse events: Eyelid ptosis (0.17%), brow ptosis (0.13%), lateral brow elevation (0.04%)
Source: BioPharm International, July 2026; AbbVie PRNewswire, July 17, 2026
What Patients Actually Want: Consumer Research Data
yet many have not taken the first step
Is a 2–3 Week Duration Actually a Benefit? An Honest Assessment
The short duration is Boey®’s defining feature —
but whether it is an advantage depends entirely on what the patient is trying to achieve.
Here is an honest breakdown.
— First-time patients who want to try a neuromodulator
without committing to months of results they may not like.
— People preparing for a specific event (wedding, photoshoot, reunion)
who want temporary improvement without long-term effects.
— Patients who need rapid onset — results as early as 8 hours
may suit last-minute situations.
— Patients who have developed resistance to Serotype A products
and need an alternative mechanism.
— A 2–3 week duration means more frequent clinic visits to maintain results.
The cumulative cost may be higher than conventional Botox.
— Current approval covers glabellar lines only.
Efficacy for forehead, crow’s feet, and other areas has not yet been established.
— Long-term comparative data against Serotype A products remains limited.
Real-world clinical experience is still being accumulated.
— Commercial availability in Europe and Canada is still being rolled out.
Actual patient access may lag behind the approval date.
What About Other Markets? The Global Approval Landscape
For markets outside the EU and Canada, no official approval timelines have been announced by AbbVie as of July 2026.
In countries with independent regulatory frameworks —
including the United States, Japan, South Korea, and Australia —
separate clinical data submissions and review processes are required.
The EU and Canadian approvals represent a meaningful proof of concept for regulators worldwide,
but they do not automatically accelerate approval in other jurisdictions.
The concept of choosing how long a treatment lasts has the potential to reshape how patients approach aesthetic medicine.
The traditional decision framework — “Do I want Botox or not?” —
is being replaced by a more nuanced question:
“How long do I want this effect to last?”
That shift lowers the psychological barrier to entry for first-time patients,
and opens new clinical conversations about personalized treatment design.
At the same time, more options require more informed decision-making.
The availability of a short-duration product does not make the choice simpler —
it makes clarity about personal goals more important than ever.
The core fear around Botox has always been the same:
“What if I can’t undo it?”
What Boey® offers is not just a shorter duration —
it offers a different relationship with reversibility.
That is as much a cultural shift in aesthetic medicine
as it is a pharmacological one.
To be direct: a 2–3 week duration is not a universal advantage.
For patients who want sustained results,
it means returning to the clinic every few weeks —
and that has real cost and time implications.
More choices are valuable.
But more choices also demand greater clarity about what you actually want.
Know your goal before you choose your tool.
Summary
- On July 17, 2026, Allergan Aesthetics (AbbVie) received EU approval for Boey® (trenibotulinumtoxinE),
covering all 30 EEA member states.
Canada approved the product in June 2026 as the first country globally. - Boey® is the world’s first Serotype E botulinum toxin approved for aesthetic use.
Onset occurs as early as 8 hours; effects resolve in approximately 2–3 weeks.
Current approval is limited to glabellar (frown) lines. - The U.S. FDA issued a Complete Response Letter (CRL) in April 2026,
requesting additional manufacturing data only.
Safety and efficacy were not cited as concerns.
AbbVie intends to respond within months. - The short duration is a genuine advantage for first-time patients and event-specific use —
but it also means more frequent visits and higher maintenance costs for those seeking sustained results.
No approval timeline has been announced for Japan or other markets as of July 2026.
Conventional Botox (Serotype A) is well-suited for patients who want 3–6 months of sustained results
and are comfortable with the product’s established track record.
Boey® (Serotype E) is designed for a different use case:
patients who want to trial a neuromodulator,
those seeking temporary improvement for a specific occasion,
or those who have developed resistance to Serotype A products.
The right choice depends on individual goals —
and should be made in consultation with a qualified clinician.
Source: AbbVie PRNewswire, July 17, 2026; BioPharm International, July 2026
approximately 6 months or longer, approved in the United States.
Boey® moves in the opposite direction:
a Serotype E product designed for shorter duration of approximately 2–3 weeks.
Together with conventional Botox (3–4 months),
these products represent an emerging spectrum of duration options —
from ultra-short to ultra-long —
allowing treatment to be matched more precisely to patient goals.
Note: Neither Daxxify nor Boey® is currently approved in Japan.
requesting additional manufacturing information.
AbbVie has stated its intention to respond within months,
but no approval or launch date has been confirmed.
For other markets — including Japan, South Korea, and Australia —
no official application or approval timeline has been announced by AbbVie as of July 2026.
Independent regulatory submissions and reviews will be required in each jurisdiction.
NERO will continue to track developments as they emerge.
Sources:
1. AbbVie. “Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe.” PRNewswire. July 17, 2026.
2. “Boey (trenibotulinumtoxinE) Wins EU Approval as First Serotype E Neurotoxin for Frown Lines.” BioPharm International. July 2026.
3. AbbVie. “AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.” PRNewswire. April 23, 2026.
4. “TrenibotulinumtoxinE Scores EU Nod for the Temporary Smoothing of Glabellar Lines.” The Dermatology Digest. July 2026.
5. Clival Database. “European Commission Approves Allergan Aesthetics’ Boey for Temporary Improvement of Frown Lines.” July 21, 2026.
6. Allergan Aesthetics Holistic Beauty Global Research. REF-148616. January 2026.
